Climb Bio Inc (CLYM)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Climb Bio, Inc. — PRE 14A Filing
# 📄 What This Document Is This is a **PRELIMINARY PROXY STATEMENT (PRE 14A)** for Climb Bio, Inc. Think of it as an invitation and an instruction manual for the company's annual shareholder meeting. It's "preliminary" because the final details might still be tweaked. **👉 In simple terms:** The co
Climb Bio, Inc. — 8-K Filing
# 🧾 What This Document Is This is a **Form 8-K**, a required report companies file with the SEC to announce major, material events that shareholders should know about. Think of it as a "breaking news" alert for investors. This specific 8-K from **Climb Bio, Inc. (CLYM)** is reporting a change in a
SEC filings
All filings →Insider trades
All insider trades →Climb Bio Inc has no reported insider trades in the last 90 days.